Oncogene Protein tpr met, also known as TPR-MET or TPMT, is a fusion protein resulting from a chromosomal translocation between the genes TPR (translocated promoter region) and MET (Met proto-oncogene). It is primarily associated with various types of cancer, particularly certain types of solid tumors, including gastric and lung carcinoma.
This fusion protein consists of the N-terminal coiled-coil domain of TPR fused with the intracellular signaling domain of MET. The coiled-coil domain of TPR mediates protein-protein interactions, while the intracellular domain of MET is responsible for signal transduction, promoting cell proliferation, survival, motility, and invasion.
The aberrant expression of TPR-MET arises from the fusion of the two genes, resulting in a constitutively activated protein that becomes autonomous of the normal regulatory mechanisms controlling MET activity. This abnormal activation leads to uncontrolled cellular growth and survival, contributing to the development and progression of cancer.
Importantly, TPR-MET fusion protein is known to activate multiple signaling pathways, such as the Ras, PI3K, and STAT pathways, which further promote cancer growth and metastasis. Due to its crucial role in oncogenesis, TPR-MET has emerged as a target for therapeutic interventions. Understanding the mechanisms by which this fusion protein contributes to cancer progression is essential for the development of novel and effective treatments for cancers associated with TPR-MET expression.
